Background: Sorafenib, a multi-kinase inhibitor targeting kinases such as RAF, VEGFR-2, and PDGFR, has demonstrated efficacy in various canine carcinomas, including hepatocellular carcinoma (HCC) and transitional cell carcinoma (TCC)
Objective: Evaluate Sorafenib's tolerability and efficacy in the treatment of various advanced canine carcinomas. Animals: Study included 9 client-owned dogs diagnosed with various unresectable or metastatic carcinomas: HCC (n=4), cholangiocarcinoma (n=1), TCC (n=1), nasal carcinoma (n=1), exocrine pancreatic carcinoma (n=1), and undefined hepatic carcinoma (n=1).
Methods: A prospective clinical trial was performed with 9 dogs. Clinical benefit (CB) was defined as the percentage of dogs achieving complete response, partial response (PR), and stable disease (SD). Progression-free interval (PFI) was defined as the interval between the first day of sorafenib and the day of disease progression. Toxicity was graded according to VCOG-CTCAE
Results: Sorafenib median dosage: 6mg/kg PO, once daily (range, 5–7.1). Median treatment duration: 88 days (range, 14-210). To date, two dogs achieved PR, 4 were stable, and 3 progressed, resulting in an overall CB of 75%. Overall PFI was 86 days (range, 0-210). Seven dogs, not previously reported, exhibited improved appetite and increased body weight, indicative of clinical benefit. One unresectable cholangiocarcinoma case with hepatic failure improved by day 16, and one recurrent hepatocellular carcinoma decreased in volume over 70 days. No significant adverse effects were observed.Conclusions and Clinical Importance: The results of this study suggest that sorafenib offers favorable clinical benefit with observed improvements and a positive safety profile.
